Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.6510
-0.0219 (-3.25%)
At close: Apr 1, 2025, 4:00 PM
0.6700
+0.0190 (2.92%)
After-hours: Apr 1, 2025, 4:31 PM EDT

Company Description

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.

The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.

Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Therapeutics, Inc.
Atossa Therapeutics logo
Country United States
Founded 2009
IPO Date Nov 8, 2012
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Steven Quay

Contact Details

Address:
107 Spring Street
Seattle, Washington 98104
United States
Phone 206 588 0256
Website atossatherapeutics.com

Stock Details

Ticker Symbol ATOS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001488039
CUSIP Number 04962H506
ISIN Number US04962H5063
Employer ID 26-4753208
SIC Code 2834

Key Executives

Name Position
Dr. Steven C. Quay FCAP, M.D., Ph.D. Chairman, Chief Executive Officer and President
Heather Rees CPA Chief Financial Officer
Delly Behen P.H.R. Senior Vice President of Administration and Human Resources
Michael Parks Vice President of Investor and Public Relations
Dr. Richard Graydon M.D., Ph.D. Interim Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 26, 2025 ARS Filing
Mar 26, 2025 DEF 14A Other definitive proxy statements
Mar 26, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 25, 2025 10-K Annual Report
Mar 25, 2025 8-K Current Report
Mar 12, 2025 8-K Current Report
Feb 24, 2025 8-K Current Report
Feb 7, 2025 SCHEDULE 13G/A Filing
Feb 4, 2025 8-K Current Report
Dec 10, 2024 8-K Current Report